Well, over the past few years, important appropriate use guidelines have been published and they provide a very strong framework for prescribing and for monitoring ATTs. But as the treatment moves into routine clinical practice, the focus of education is, I think, beginning to shift and we’re moving from simply just determining treatment eligibility to refining patient selection. And current recommendations focus mainly on identifying patients with early Alzheimer’s disease and confirmed amyloid pathology...
Well, over the past few years, important appropriate use guidelines have been published and they provide a very strong framework for prescribing and for monitoring ATTs. But as the treatment moves into routine clinical practice, the focus of education is, I think, beginning to shift and we’re moving from simply just determining treatment eligibility to refining patient selection. And current recommendations focus mainly on identifying patients with early Alzheimer’s disease and confirmed amyloid pathology. And of course, excluding individuals with clear safety risks, such as high burden of microhemorrhages. But within this eligible population, there is still considerable variability in both treatment response and ARIA risk, which we also see in our study. So the challenge now, I think, is learning how to identify which patients are most likely to benefit from treatment and which may have higher biological vulnerability to complications. And this is where imaging and biomarkers become increasingly important. Our findings suggest that beyond eligibility criteria, clinicians may need to adopt a more biologically informed approach to patient selection and to integrate structural MRI measures, vascular imaging markers, genetic risk factors, and additional biomarkers. And the second educational gap, I think, relates to the more operational and multidisciplinary aspects of the treatment because prescribing anti-amyloid therapies is not simply writing a prescription. It requires a real coordination between neurologists and radiologists and infusion units and nurses and genetic counseling and biomarker laboratories and many centers, including us, are still developing the optimal clinical workflows that are needed to deliver these therapies safely and efficiently. And I think that as more real-world data become available, continued education, shared clinical experience will really help us to refine these practices and to move the field toward a more personalized treatment framework for Alzheimer’s patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
